Literature DB >> 2692333

Immunogenicity of liposomal malaria sporozoite antigen in monkeys: adjuvant effects of aluminium hydroxide and non-pyrogenic liposomal lipid A.

R L Richards1, G M Swartz, C Schultz, M D Hayre, G S Ward, W R Ballou, J D Chulay, W T Hockmeyer, S L Berman, C R Alving.   

Abstract

The immunogenicity of a recombinant protein (R32tet32) containing sequences from the tetrapeptide repeat region of the circumsporozoite protein of Plasmodium falciparum was enhanced by encapsulation in liposomes containing lipid A and adsorption of the liposomes with alum. The toxicities and efficacies of preparations containing different types and doses of lipid A were assessed by studying pyrogenicity in rabbits and adjuvanticity in monkeys. In each case liposomal lipid A was 25-fold to 200-fold less pyrogenic than free lipid A. Monophosphoryl lipid A, whether free or in liposomes, was the least pyrogenic of the three lipid A preparations tested. High antibody levels were obtained after immunization of rhesus monkeys with a formulation consisting of alum-adsorbed liposomes in which the liposomes contained R32tet32 and a strongly pyrogenic dose of native lipid A. Excellent antibody levels were also observed in monkeys immunized with a combination of R32tet32 encapsulated in alum-adsorbed liposomes containing non-pyrogenic doses of monophosphoryl lipid A and alum. The adjuvant effect was related to the dose of the lipid A in the liposomes, and the adjuvant effect was still strongly expressed despite suppression of the pyrogenic effect of lipid A. Antibody levels were considerably lower in monkeys immunized with liposomes lacking lipid A. It was concluded that a non-pyrogenic formulation of alum-adsorbed liposomes, in which the liposomes contained both lipid A and an encapsulated synthetic sporozoite antigen, shows considerable promise for inducing high titres of antibodies to sporozoites.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2692333     DOI: 10.1016/0264-410x(89)90274-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Adjuvant effects of liposomes containing lipid A: enhancement of liposomal antigen presentation and recruitment of macrophages.

Authors:  J N Verma; M Rao; S Amselem; U Krzych; C R Alving; S J Green; N M Wassef
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

2.  Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen.

Authors:  N K Childers; K L Miller; G Tong; J C Llarena; T Greenway; J T Ulrich; S M Michalek
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

3.  Effectiveness of liposomes possessing surface-linked recombinant B subunit of cholera toxin as an oral antigen delivery system.

Authors:  E Harokopakis; G Hajishengallis; S M Michalek
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

4.  Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy.

Authors:  L F Fries; D M Gordon; R L Richards; J E Egan; M R Hollingdale; M Gross; C Silverman; C R Alving
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

Review 5.  Immunopotentiation and delivery systems for antigens for single-step immunization: recent trends and progress.

Authors:  M Z Khan; J P Opdebeeck; I G Tucker
Journal:  Pharm Res       Date:  1994-01       Impact factor: 4.200

Review 6.  Army Liposome Formulation (ALF) family of vaccine adjuvants.

Authors:  Carl R Alving; Kristina K Peachman; Gary R Matyas; Mangala Rao; Zoltan Beck
Journal:  Expert Rev Vaccines       Date:  2020-03-31       Impact factor: 5.217

7.  Adjuvants for Leishmania vaccines: from models to clinical application.

Authors:  Vanitha S Raman; Malcolm S Duthie; Christopher B Fox; Greg Matlashewski; Steven G Reed
Journal:  Front Immunol       Date:  2012-06-11       Impact factor: 7.561

Review 8.  Induction of Plasmodium-Specific Immune Responses Using Liposome-Based Vaccines.

Authors:  Aloysious Ssemaganda; Ashwini Kumar Giddam; Mehfuz Zaman; Mariusz Skwarczynski; Istvan Toth; Danielle I Stanisic; Michael F Good
Journal:  Front Immunol       Date:  2019-02-01       Impact factor: 7.561

Review 9.  The Use of Synthetic Carriers in Malaria Vaccine Design.

Authors:  Liam Powles; Sue D Xiang; Cordelia Selomulya; Magdalena Plebanski
Journal:  Vaccines (Basel)       Date:  2015-10-29

Review 10.  Liposomes for malaria management: the evolution from 1980 to 2020.

Authors:  Patrick B Memvanga; Christian I Nkanga
Journal:  Malar J       Date:  2021-07-27       Impact factor: 2.979

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.